Analyzing Solid Biosciences (NASDAQ:SLDB) & Ambrx Biopharma (NYSE:AMAM)

Solid Biosciences (NASDAQ:SLDBGet Free Report) and Ambrx Biopharma (NYSE:AMAMGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Solid Biosciences and Ambrx Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 0 0 6 0 3.00
Ambrx Biopharma 0 4 4 0 2.50

Solid Biosciences currently has a consensus price target of $18.25, indicating a potential upside of 75.99%. Ambrx Biopharma has a consensus price target of $24.13, indicating a potential downside of 13.84%. Given Solid Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than Ambrx Biopharma.

Risk and Volatility

Solid Biosciences has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Ambrx Biopharma has a beta of -1.92, meaning that its share price is 292% less volatile than the S&P 500.

Profitability

This table compares Solid Biosciences and Ambrx Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A -62.11% -48.99%
Ambrx Biopharma N/A N/A N/A

Institutional and Insider Ownership

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 77.3% of Ambrx Biopharma shares are owned by institutional investors. 19.3% of Solid Biosciences shares are owned by insiders. Comparatively, 0.6% of Ambrx Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Solid Biosciences and Ambrx Biopharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences $8.09 million 48.40 -$96.01 million ($4.84) -2.14
Ambrx Biopharma $7.40 million 238.95 -$78.00 million N/A N/A

Ambrx Biopharma has lower revenue, but higher earnings than Solid Biosciences.

Summary

Solid Biosciences beats Ambrx Biopharma on 7 of the 11 factors compared between the two stocks.

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

About Ambrx Biopharma

(Get Free Report)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.